AI Summary
FDA rejects Clene Nanomedicine's application for accelerated approval of ALS drug CNM-Au8 due to lack of evidence.
The FDA has rejected Clene Nanomedicine’s application for accelerated approval for the experimental drug ALS drug, CNM-Au8, citing insufficient evidence.
Medscape Medical News